XML 37 R24.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Note O - Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Income Tax Disclosure [Text Block] | NOTE O—INCOME TAXES The sources of the Company’s loss from operations before income taxes were as follows (in thousands):
|  | Years ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Domestic |  | $ | (181,701 | ) |  | $ | (52,886 | ) |  | $ | (45,404 | )
Foreign |  |  | (5,030 | ) |  |  | (3,153 | ) |  |  | (20,992 | )
Total loss before income taxes |  | $ | (186,731 | ) |  | $ | (56,039 | ) |  | $ | (66,396 | )
The provision for income tax expense (benefit) for the years ended December 31, was as follows (in thousands):
Current: |  | 2024 |  |  | 2023 |  |  | 2022 |
Federal |  | $ | — |  |  | $ | — |  |  | $ | — |
State |  |  | 2 |  |  |  | 1 |  |  |  | 1 |
Foreign |  |  | — |  |  |  | 8 |  |  |  | — |
Total |  | $ | 2 |  |  | $ | 9 |  |  | $ | 1 |
Deferred: |  |  |  |  |  |  |  |  |  |  |  |
Federal |  | $ | — |  |  | $ | — |  |  | $ | — |
State |  |  | — |  |  |  | — |  |  |  | — |
Foreign |  |  | — |  |  |  | — |  |  |  | — |
Total |  | $ | — |  |  | $ | — |  |  | $ | — |
Income tax (benefit) expense |  | $ | 2 |  |  | $ | 9 |  |  | $ | 1 |
Deferred income tax assets and liabilities result principally from net operating losses, different methods of recognizing depreciation, reserves for doubtful accounts and inventory, research and development credits and foreign tax credits. At December 31, the net deferred tax assets and liabilities are comprised of the following approximate amounts (in thousands):
|  | 2024 |  |  | 2023 |
NOL carryforward |  | $ | 59,788 |  |  | $ | 49,469 |
Inventory reserves |  |  | 3,700 |  |  |  | 3,195 |
Unrealized gains and losses |  |  | 221 |  |  |  | 355 |
Share-based compensation |  |  | 1,332 |  |  |  | 1,013 |
Foreign tax credit |  |  | 4,599 |  |  |  | 4,599 |
Research and development credits |  |  | 12,508 |  |  |  | 10,998 |
Capitalized research and development |  |  | 14,449 |  |  |  | 8,717 |
Interest |  |  | 4,465 |  |  |  | 5,659 |
ASC 842 Assets |  |  | 1,515 |  |  |  | 1,561 |
Other |  |  | 995 |  |  |  | 941 |
Deferred tax assets |  |  | 103,572 |  |  |  | 86,507 |
Less valuation allowance |  |  | (94,996 | ) |  |  | (78,124 | )
Deferred tax assets, net |  |  | 8,576 |  |  |  | 8,383 |
Depreciation and amortization |  |  | (7,216 | ) |  |  | (6,992 | )
ASC 842 Liabilities |  |  | (1,360 | ) |  |  | (1,391 | )
Deferred tax liabilities |  |  | (8,576 | ) |  |  | (8,383 | )
Deferred tax assets, net |  | $ | — |  |  | $ | — |
The Company has a U.S. net operating loss carry forward of approximately $147.3 million, $32.7 million of which, if unused, expires between 2026 and 2032 and $114.6 million of which, can be carried forward indefinitely. The Company has U.S. and state research and development tax credits of $12.5 million, which, if unused, expire between 2028 and 2043. In addition, the Company has foreign tax credits of $4.6 million, which, if unused, will expire in 2028. Utilization of U.S. net operating losses and tax credit carry forwards are subject to an annual limitation due to the ownership change limitations set forth in Internal Revenue Code Section 382. As of December 31, 2024, the Company had Taiwan net operating loss carry forwards of approximately $77.7 million and China net operating loss carry forwards of approximately $74.7 million. The carryforward period for the Taiwan net operating loss carry forwards is ten years, and the expiration period begins 2028. The carryforward period for China net operating loss carry forwards is ten years, and the expiration period begins 2029. Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2024. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. On the basis of this evaluation, as of December 31, 2024 and December 31, 2023, a valuation allowance of $95.0 million and $78.1 million, respectively, has been recorded to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. The following table shows the change in the deferred tax valuation allowance as follows:
|  | 2024 |  |  | 2023 |  |  | 2022 |
Beginning Balance, January 1 |  | $ | 78,124 |  |  | $ | 69,680 |  |  | $ | 57,721 |
Change charged to expense/(income) |  |  | 15,727 |  |  |  | 8,755 |  |  |  | 14,196 |
Change charged to currency translation adjustment |  |  | 1,145 |  |  |  | (311 | ) |  |  | (2,237 | )
Ending Balance, December 31 |  | $ | 94,996 |  |  | $ | 78,124 |  |  | $ | 69,680 |
A reconciliation of the U.S. federal income tax rate of 21% for the years ended December 31, 2024, 2023 and 2022, respectively, to the Company’s effective income tax rate follows (in thousands):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Expected taxes at statutory rate |  | $ | (39,214 | ) |  | $ | (11,768 | ) |  | $ | (13,943 | )
Interest Carryforward |  |  | 1,843 |  |  |  | — |  |  |  | — |
Non-deductible/non-taxable items |  |  | 470 |  |  |  | 57 |  |  |  | 33 |
Global intangible low-taxed income |  |  | 1,809 |  |  |  | 2,568 |  |  |  |  |
Foreign rate differences |  |  | (314 | ) |  |  | 242 |  |  |  | 552 |
Foreign permanent differences |  |  | (1,245 | ) |  |  | (1,212 | ) |  |  | (1,407 | )
Changes in valuation allowance |  |  | 15,727 |  |  |  | 8,755 |  |  |  | 14,196 |
Share-based compensation |  |  | 222 |  |  |  | 729 |  |  |  | 879 |
Research and development credits |  |  | (1,510 | ) |  |  | (492 | ) |  |  | (626 | )
Extinguishment of debt |  |  | 22,602 |  |  |  | 1,580 |  |  |  | — |
Foreign other |  |  | — |  |  |  | — |  |  |  | — |
Other, net |  |  | (388 | ) |  |  | (450 | ) |  |  | 317 |
Tax (benefit) expense |  | $ | 2 |  |  | $ | 9 |  |  | $ | 1 |
The Company's provision for income taxes in 2024 was higher than 2023 primarily due to state taxes. The Company's provision for income taxes in 2023 was higher than 2022 primarily due to state taxes and foreign taxes. The Company’s wholly owned subsidiary, Prime World is a tax-exempt entity under the Income Tax Code of the British Virgin Islands. The Company’s wholly owned subsidiary, Global Technology, Inc., has enjoyed preferential tax concessions in China as a national high-tech enterprise. In March 2007, China’s parliament enacted the PRC Enterprise Income Tax Law, or the EIT Law, under which, effective January 1, 2008, China adopted a uniform income tax rate of 25% for all enterprises including foreign invested enterprises. However, Global Technology, Inc. has been recognized as a National high-tech enterprise since 2008 and entitled to a 15% reduced tax rate. In December 2023, Global Technology, Inc. again renewed its National high-tech enterprise certificate and therefore extended its three-year tax preferential status﻿ until December 2026. This tax holiday reduced its 2024, 2023 and 2022 income tax provision by approximately $0.0 million, $0.0 million, and $0.0 million, respectively. This tax holiday reduced its fiscal 2024, 2023, and 2022 diluted earnings per share by approximately $0.00, $0.00, and $0.00 respectively. Effective January 1, 2016, China expanded the scope of the National high-tech enterprise to include additional deductions for qualifying research and development. As of December 31, 2024, 2023 and 2022, the total amount of unrecognized tax benefit was $0.2 million, $0.2 million, and $0.2 million, respectively. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Unrecognized tax benefits — January 1 |  | $ | 181 |  |  | $ | 181 |  |  | $ | 181 |
Gross increases — tax positions in prior period |  |  | — |  |  |  | — |  |  |  | — |
Gross decreases — tax positions in prior period |  |  | — |  |  |  | — |  |  |  | — |
Unrecognized tax benefits — December 31 |  | $ | 181 |  |  | $ | 181 |  |  | $ | 181 |
The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, it has not accrued penalties or interest during 2024 as a result of net operating losses. During 2023 or 2022, the Company also accrued no penalties or interest. The Company is subject to taxation in the United States and various states and foreign jurisdictions. The Company’s open tax years subject to examination in the U.S. federal and state jurisdictions are 2021 through 2024. To the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses or tax credits were generated and carried forward, and make adjustments up to the amount of the net operating loss or tax credit carryforward. The Company is subject to examination for tax years 2019 forward for various foreign jurisdictions. In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (“QIP”). On December 27, 2020, the Taxpayer Certainty and Disaster Tax Relief Act of 2020 was enacted as part of the Consolidated Appropriations Act, 2021, followed by the American Rescue Plan Act on March 1, 2021. These laws, among many other provisions, expand and extend the Paycheck Protection Program (“PPP”), refundable employee retention tax credits previously made available under the CARES Act and allow a full deduction for business meals for the 2021 and 2022 tax years. During 2021, the Company recognized a tax benefit of $1.3 million on the non-taxable forgiveness of the PPP loan. However, the legislation had no material impact to income tax expense on the Company’s financial statements as a result of our valuation allowance. On August 9, 2022, the Creating Helpful Incentives to Produce Semiconductors and Science Act, (the “CHIPS Act”) was signed into law. Among other things, the CHIPS Act provides for refundable tax credits and certain other financial incentives to further investments in domestic manufacturing. At least a portion of our current and future capital expenditures and research and development costs will qualify for this credit, which benefits us by allowing us to net the credit received against our costs. This credit is accounted for outside of ASC 740 as a reduction to the depreciable basis of the assets used in operations and will not have an impact on our effective tax rate. On August 16, 2022, legislation commonly known as the Inflation Reduction Act was signed into law. Among other things, the Inflation Reduction Act includes a 1% excise tax on corporate stock repurchases, applicable to repurchases after December 31, 2022, and also a new minimum tax based on book income. We do not currently expect the Inflation Reduction Act to have a material impact on our effective tax rate. The Company expects any earnings of foreign subsidiaries to be indefinitely invested outside the United States. As of December 31, 2024, however, the Company does not have any accumulated undistributed earnings generated by foreign subsidiaries and has estimated that its tax basis in foreign subsidiaries exceeds its book basis. The Company has concluded that no deferred tax asset (DTA) should be recorded because at the present time it does not expect that the temporary book-tax basis difference that would create this DTA will reverse in the foreseeable future.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration